Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations.


Journal

The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634

Informations de publication

Date de publication:
04 2019
Historique:
received: 05 04 2018
revised: 12 11 2018
accepted: 21 11 2018
pubmed: 30 11 2018
medline: 18 12 2019
entrez: 29 11 2018
Statut: ppublish

Résumé

The B cell receptor immunoglobulin (Ig) gene repertoires of marginal zone (MZ) lymphoproliferations were analyzed in order to obtain insight into their ontogenetic relationships. Our cohort included cases with MZ lymphomas (n = 488), i.e. splenic (SMZL), nodal (NMZL) and extranodal (ENMZL), as well as provisional entities (n = 76), according to the WHO classification. The most striking Ig gene repertoire skewing was observed in SMZL. However, restrictions were also identified in all other MZ lymphomas studied, particularly ENMZL, with significantly different Ig gene distributions depending on the primary site of involvement. Cross-entity comparisons of the MZ Ig sequence dataset with a large dataset of Ig sequences (MZ-related or not; n = 65 837) revealed four major clusters of cases sharing homologous ('public') heavy variable complementarity-determining region 3. These clusters included rearrangements from SMZL, ENMZL (gastric, salivary gland, ocular adnexa), chronic lymphocytic leukemia, but also rheumatoid factors and non-malignant splenic MZ cells. In conclusion, different MZ lymphomas display biased immunogenetic signatures indicating distinct antigen exposure histories. The existence of rare public stereotypes raises the intriguing possibility that common, pathogen-triggered, immune-mediated mechanisms may result in diverse B lymphoproliferations due to targeting versatile progenitor B cells and/or operating in particular microenvironments. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Identifiants

pubmed: 30484876
doi: 10.1002/path.5209
doi:

Substances chimiques

Complementarity Determining Regions 0
Immunoglobulin Variable Region 0
Receptors, Antigen, B-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

416-421

Subventions

Organisme : Blood Cancer UK
ID : 15019
Pays : United Kingdom

Informations de copyright

Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Auteurs

Aliki Xochelli (A)

Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Vasilis Bikos (V)

Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Eleftheria Polychronidou (E)

Information Technologies Institute, CERTH, Thessaloniki, Greece.
Department of Informatics, Ionian University, Corfu, Greece.

Chrysi Galigalidou (C)

Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.

Andreas Agathangelidis (A)

Division of Experimental Oncology and Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy.

Frédéric Charlotte (F)

Department of Pathology, Hopital Pitie-Salpetriere and Sorbonne University, Paris, France.

Panagiotis Moschonas (P)

Information Technologies Institute, CERTH, Thessaloniki, Greece.

Zadie Davis (Z)

Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.

Monica Colombo (M)

Molecular Pathology, Ospedale Policlinico SanMartino, Genoa, Italy.

Maria Roumelioti (M)

First Department of Propaedeutic Medicine, University of Athens, Athens, Greece.

Lesley-Ann Sutton (LA)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Patricia Groenen (P)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Michiel van den Brand (M)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Myriam Boudjoghra (M)

Department of Hematology, Hopital Pitie-Salpetriere and Sorbonne University, Paris, France.

Patricia Algara (P)

Hospital Virgen de la Salud, Toledo, Spain.

Alexandra Traverse-Glehen (A)

Department of Pathology and Hematology, Hospices Civils de Lyon Universite Lyon 1, Lyon, France.

Ana Ferrer (A)

Laboratori de Citologia Hematològica i Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain.

Evangelia Stalika (E)

Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.

Maria Karypidou (M)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

George Kanellis (G)

Hematopathology Department, Evangelismos Hospital, Athens, Greece.

Christina Kalpadakis (C)

Department of Haematology, University of Crete, Heraklion, Greece.

Manuella Mollejo (M)

Hospital Virgen de la Salud, Toledo, Spain.

Gerasimos Pangalis (G)

Department of Haematology, Athens Medical Center, Athens, Greece.

Panayiotis Vlamos (P)

Department of Informatics, Ionian University, Corfu, Greece.

Rose-Marie Amini (RM)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Sarka Pospisilova (S)

Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

David Gonzalez (D)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.

Maurilio Ponzoni (M)

Pathology Unit, San Raffaele Scientific Institute, Milan, Italy.

Achilles Anagnostopoulos (A)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

Véronique Giudicelli (V)

IMGT®, the international ImMunoGeneTics Information System®, Université de Montpellier, LIGM, Institut de Génétique Humaine IGH, UMR CNRS UM, Montpellier, France.

Marie-Paule Lefranc (MP)

IMGT®, the international ImMunoGeneTics Information System®, Université de Montpellier, LIGM, Institut de Génétique Humaine IGH, UMR CNRS UM, Montpellier, France.

Blanca Espinet (B)

Laboratori de Citologia Hematològica i Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain.

Panagiotis Panagiotidis (P)

First Department of Propaedeutic Medicine, University of Athens, Athens, Greece.

Miguel Angel Piris (MA)

Pathology Department, IIS 'Fundacion Jimenez Diaz', Madrid, Spain.

Ming-Qing Du (MQ)

Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.

Richard Rosenquist (R)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Theodora Papadaki (T)

Hematopathology Department, Evangelismos Hospital, Athens, Greece.

Chrysoula Belessi (C)

Hematology Department, Nikea General Hospital, Piraeus, Greece.

Manlio Ferrarini (M)

Direzione Scientifica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera Universitaria (AOU) San Martino-IST, Genoa, Italy.

David Oscier (D)

Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.

Dimitrios Tzovaras (D)

Information Technologies Institute, CERTH, Thessaloniki, Greece.

Paolo Ghia (P)

Division of Experimental Oncology and Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy.

Frederic Davi (F)

Department of Hematology, Hopital Pitie-Salpetriere and Sorbonne University, Paris, France.

Anastasia Hadzidimitriou (A)

Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Kostas Stamatopoulos (K)

Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH